TEAM

CEO MESSAGE

-From Science to Life-

While Japan produces a lot of outstanding medical/lifescience research, a significant gap remains between scientific discovery and patient care. This is a critical issue, especially for children and people with rare diseases who are waiting for new treatments.

Our company was founded on a simple principle: to bring treatments with strong scientific evidence directly to the patients and families who need them most.

After a long VC career at Japan Asia Investment Co., Ltd., focusing on business development and financing for the biotech and healthcare sectors, he founded Japan Regenerative Medicine Co., Ltd., leveraging his experience in launching diagnostic and regenerative medicine businesses. He led the development of cardiac stem cells, and JRM-001 became the first product in Japan to be designated for the SAKIGAKE fast-track review system for regenerative medical products. He continued to lead development alongside his management duties, assuming his current position in 2024.

TEAM

Metcela has an integrated system that manages the entire process from research to development. Our teams and projects are led by experienced professionals who have worked in pharmaceutical companies and public research institutions.